Literature DB >> 9512393

No evidence for disruption of normal patterns of mRNA localization in dendrites or dendritic transport of recently synthesized mRNA in FMR1 knockout mice, a model for human fragile-X mental retardation syndrome.

O Steward1, C E Bakker, P J Willems, B A Oostra.   

Abstract

Recent studies have revealed that FMRP, the gene product of the fragile-X gene FMR1, is an RNA-binding protein. These and other data have led to the idea that FMRP may play a role in targeting mRNAs for transport to synaptic sites. The present study evaluated whether a null mutation of FMR1 disrupts the patterns of localization of three mRNAs that are present constitutively in dendrites (the mRNAs for MAP2, CAMII kinase and dendrin), or disrupt the rapid dendritic transport of the mRNA for activity-regulated cytoskeletal protein (ARC), coded for by an immediate-early gene. In situ hybridization analyses revealed that the patterns of mRNA localization in dendrites and the dendritic transport of ARC mRNA are indistinguishable from normal in FMR1 knockout mice. These results indicate that FMRP does not play an obligatory role in targeting this set of mRNAs to dendrites, although it might be involved in targeting other dendritic mRNAs yet to be identified.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512393     DOI: 10.1097/00001756-199802160-00022

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  19 in total

Review 1.  Candidate RNA-binding proteins regulating extrasomatic mRNA targeting and translation in mammalian neurons.

Authors:  Stefan Kindler; Michaela Monshausen
Journal:  Mol Neurobiol       Date:  2002-04       Impact factor: 5.590

2.  Subcellular localization of fragile X mental retardation protein with the I304N mutation in the RNA-binding domain in cultured hippocampal neurons.

Authors:  M Castrén; A Haapasalo; B A Oostra; E Castrén
Journal:  Cell Mol Neurobiol       Date:  2001-02       Impact factor: 5.046

3.  Evidence for a fragile X mental retardation protein-mediated translational switch in metabotropic glutamate receptor-triggered Arc translation and long-term depression.

Authors:  Farr Niere; Julia R Wilkerson; Kimberly M Huber
Journal:  J Neurosci       Date:  2012-04-25       Impact factor: 6.167

Review 4.  Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function.

Authors:  Gary J Bassell; Stephen T Warren
Journal:  Neuron       Date:  2008-10-23       Impact factor: 17.173

5.  Alterations in CA1 hippocampal synapses in a mouse model of fragile X syndrome.

Authors:  Safdar Jawaid; Grahame J Kidd; Jing Wang; Carrie Swetlik; Ranjan Dutta; Bruce D Trapp
Journal:  Glia       Date:  2017-12-23       Impact factor: 7.452

6.  UPF1 Governs Synaptic Plasticity through Association with a STAU2 RNA Granule.

Authors:  Tyson E Graber; Erika Freemantle; Mina N Anadolu; Sarah Hébert-Seropian; Robyn L MacAdam; Unkyung Shin; Huy-Dung Hoang; Tommy Alain; Jean-Claude Lacaille; Wayne S Sossin
Journal:  J Neurosci       Date:  2017-08-18       Impact factor: 6.167

Review 7.  CGG repeat in the FMR1 gene: size matters.

Authors:  R Willemsen; J Levenga; B A Oostra
Journal:  Clin Genet       Date:  2011-06-30       Impact factor: 4.438

8.  The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain.

Authors:  Armaz Aschrafi; Bruce A Cunningham; Gerald M Edelman; Peter W Vanderklish
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

Review 9.  Translational control of long-lasting synaptic plasticity and memory.

Authors:  Mauro Costa-Mattioli; Wayne S Sossin; Eric Klann; Nahum Sonenberg
Journal:  Neuron       Date:  2009-01-15       Impact factor: 17.173

10.  A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome.

Authors:  Jason B Dictenberg; Sharon A Swanger; Laura N Antar; Robert H Singer; Gary J Bassell
Journal:  Dev Cell       Date:  2008-06       Impact factor: 12.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.